TG Therapeutics Logo
US88322Q1085
A1JXW7
TGTX

TG Therapeutics

Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 73,31 € (+19,98 %). Medianen er 73,31 € (+19,98 %).

Køb
  11
Behold
  1
Sælg
  1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • TG Therapeutics raises revenue outlook, BRIUMVI gains market share in RMS

    TG Therapeutics reports strong commercial growth of BRIUMVI in relapsing multiple sclerosis and raises its 2024 revenue guidance to $890–905 million; the company is targeting a $1 billion run rate by the end of Q4. BRIUMVI has captured more than one-third of the IV anti‑CD20 market, a simplified IV dosing regimen should ease use, and a sBLA is upcoming. A subcutaneous formulation showed about 60% bioavailability in Phase I and will be tested in Phase III against two dosing intervals; TG sees broad potential also in myasthenia gravis and treatment‑resistant schizophrenia. » Mere på de.investing.com


  • TG Therapeutics stock recovers despite earnings miss

    TG Therapeutics shares rose intraday by 5.9%, extending the recovery after the sharp sell-off following the Q2 results. The company reported EPS of $0.05 versus a consensus of about $0.44; the miss was due to higher manufacturing and operating costs, not weak revenue. Revenue increased in the second quarter to roughly $240 million (+70% YoY) and the full-year guide was raised to about $950 million; additionally, the completed enrollment of the phase-3 trial for subcutaneous BRIUMVI administration could be another catalyst. » Mere på de.investing.com


  • TG Therapeutics climbs after Briumvi outperforms expectations and positive subcutaneous data

    ClearBridge's Q2 investor letter named TG Therapeutics as a top contributor after its key drug Briumvi delivered greater-than-expected growth and positive clinical results for a subcutaneous formulation that could expand the addressable market. The stock has risen sharply over the past month and year, reflecting renewed investor interest in the company's commercial-stage multiple sclerosis franchise. » Mere på finance.yahoo.com


  • TG Therapeutics hits 52-week high at $57.40

    Shares of TG Therapeutics rose to a 52-week high of $57.40 and are up about 86% year-to-date, bringing market capitalization to $8.09 billion. InvestingPro currently rates the stock as undervalued compared with its fair value. For Q1 2026 the company missed EPS expectations ($0.12 vs. $0.28) and reported slightly lower revenue of $194.8 million. TG Therapeutics is simultaneously advancing clinical programs with Briumvi, including initiated Phase 2 studies in treatment‑resistant schizophrenia and myasthenia gravis, positive post‑hoc Phase 3 data, and a successful ENHANCE study endpoint demonstrating bioequivalence of a new single‑dose infusion regimen. » Mere på de.investing.com


  • TG Therapeutics reaches 52-week high at 54.04 USD

    Shares of TG Therapeutics rose to a 52-week high of 54.04 USD, giving the company a market capitalization of about 7.57 billion USD; the stock is up 72.76% year-to-date and gained 52.54% over the past year. Despite the share price increase, the company missed Q1 2026 estimates with EPS of 0.12 USD (expectation 0.28 USD) and revenue of 194.8 million USD (forecast 199.45 million USD). TG Therapeutics also reported progress with BRIUMVI: start of a phase-2 maintenance study in myasthenia gravis, positive phase-1 topline data and positive post-hoc results, and a successful ENHANCE bioequivalence study in multiple sclerosis. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde TG Therapeutics en omsætning på 229,48 mio. € og et nettoresultat på 48,97 mio. €
(EUR) september 2026
YoY
Omsætning 229,48 mio. 66,54 %
Bruttofortjeneste 192,34 mio. 69,00 %
Nettoresultat 48,97 mio. 85,30 %
EBITDA 79,24 mio. 184,44 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
8,64 mia. €
Antal aktier
151,15 mio.
Højeste/laveste i 52 uger
61,96 € - 24,37 €
Udbytte Nej
Beta
1,81
P/E (PE Ratio)
84,25
PEG (PEG Ratio)
-1,11
K/I (PB Ratio)
15,44
P/S (PS Ratio)
10,57

Virksomhedsprofil

TG Therapeutics, Inc., et kommercielt biofarmaceutisk selskab, fokuserer på erhvervelse, udvikling og kommercialisering af nye behandlinger for B-celle-maligniteter og autoimmune sygdomme. Selskabets terapeutiske produktkandidater omfatter Ublituximab, et undersøgelsesstadie glycoengineeret monoklonalt antistof til behandling af B-celle non-Hodgkin-lymfom, kronisk lymfocytisk leukæmi (CLL) og recidiverende former for multipel sklerose; og Umbralisib, en oral hæmmer af PI3K-delta og CK1-epsilon til behandling af CLL, marginalzonelymfom og follikulært lymfom. Selskabet udvikler desuden Cosibelimab, et humant monoklonalt antistof af IgG1-subtypen, der binder sig til programmed death-ligand 1 (PD-L1) og blokerer dets interaktioner med PD-1- og B7.1-receptorerne; TG-1701 er en oralt tilgængelig og kovalent bundet Bruton's tyrosinkinase (BTK)-hæmmer, der i in vitro-kinasescreeninger viser selektivitet over for BTK sammenlignet med ibrutinib; og TG-1801, et bispecifikt CD47- og CD19-antistof. Derudover har selskabet forskellige licenserede prækliniske programmer for BET, interleukin-1-receptorassocieret kinase-4 og GITR; samt samarbejdsaftaler med Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated og Jubilant Biosys. Selskabet har strategiske alliancer med LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd. og Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. blev stiftet i 1993 og har hovedkontor i New York, New York.

Navn
TG Therapeutics
CEO
Michael S. Weiss
Hjemsted Morrisville, ny
USA
Websted
Sektor
Sundhed
Branche
Bioteknologi
Børsnotering
03.05.2010
Medarbejdere 399

Tickersymboler

Børs Symbol
NASDAQ
TGTX
London Stock Exchange
0VGI.L
Frankfurt
NKB2.F
Düsseldorf
NKB2.DU
London
0VGI.L
SIX
NKB2.SW
München
NKB2.MU
🍪

Parqet  bruger cookies. Læs mere